# US 2025/0367115 A1 · Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367115 A1
- Document ID: US20250367115A1
- Status: Published application
- Kind: A1
- Application number: 19/025,406
- Filed: 2025-01-16
- Published: 2025-12-04
- Earliest claimed: 2017-04-28
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Jian Hua GU; Robert M. FESINMEYER; Rulin QIAN
- Web page: https://patentgrep.com/patent/US20250367115A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/40: against enzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.

## Claims

### Claim 1

A liquid pharmaceutical formulation comprising an antibody, a buffer, and at least one oligopeptide, wherein (i) the oligopeptide comprises an arginine residue and consists of 2 to 10 amino acid residues but is not arg-asp, arg-glu, or poly-arginine, (ii) the buffer is acetate, glutamate, or phosphate and (iii) the pH of the formulation is about 4.5 to about 6.5.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the antibody is present in a concentration of at least about:
a. 70 mg/mL,
b. 85 mg/mL,
c. 100 mg/mL,
d. 130 mg/mL,
e. 160 mg/mL
f. 200 mg/mL, or
g. 200 mg/mL to about 400 mg/mL.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the antibody is selected from adalimumab, bevacizumab, blinatumomab, cetuximab, conatumumab, denosumab, eculizumab, erenumab, evolocumab, a PCSK9 binding polypeptide, infliximab, natalizumab, panitumumab, prezalumab, rilotumumab, rituximab, romosozumab, tezepelumab, and trastuzumab, or comprises the heavy chain and light chain sequences of an antibody selected from Table 2.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the oligopeptide has a concentration of:
a. about 10 mM to about 500 mM or
b. about 100 mM to about 200 mM.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the oligopeptide is an acetate salt.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the oligopeptide is selected from Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, Phe-Arg, Arg-Tyr, and Ala-Arg,.

### Claim 7 (depends on 1)

The formulation of claim 1, further comprising (i) a second oligopeptide comprising arginine and consisting of two to 10 amino acid residues, wherein the second oligopeptide is a dipeptide comprising a basic, acidic, hydrophobic, or aromatic residue, (ii) one or more amino acids, or (iii) mixtures of any thereof.

### Claim 8 (depends on 8)

The formulation of claim 8, wherein the second oligopeptide is selected from Arg-Lys, Arg-Pro, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Val-Arg, Ala-Arg, Phe-Arg, and Arg-Tyr and the one or more amino acids are selected from arginine, proline, n-acetyl arginine, n-acetyl lysine, n-acetyl histidine, n-acetyl proline.

### Claim 9

A method of reducing viscosity in a pharmaceutical formulation comprising an antibody, wherein the method comprises:
providing a solution at a pH of about 4.5 to about 6.5 comprising (i) the antibody, (ii) an oligopeptide salt, wherein the oligopeptide comprises an arginine residue, consists of 2 to 10 amino acid residues and is present in a viscosity-reducing concentration, and (iii) a buffer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody is present in a concentration of at least about:
a. 70 mg/mL,
b. 85 mg/mL,
c. 100 mg/mL,
d. 130 mg/mL,
e. 160 mg/mL
f. 200 mg/mL, or
g. 200 mg/mL to about 400 mg/mL.

### Claim 11 (depends on 9)

The method of claim 9, wherein the antibody is selected from adalimumab, bevacizumab, blinatumomab, cetuximab, conatumumab, denosumab, eculizumab, erenumab, evolocumab, a PCSK9 binding polypeptide, infliximab, natalizumab, panitumumab, rilotumumab, rituximab, romosozumab, tezepelumab, and trastuzumab, or comprises the heavy chain and light chain sequences of an antibody selected from Table 2.

### Claim 12 (depends on 9)

The method of claim 9, wherein the oligopeptide has a concentration of:
a. about 10 mM to about 500 mM or
b. about 100 mM to about 200 mM.

### Claim 13 (depends on 9)

The method of claim 9, wherein the oligopeptide is selected from Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, Phe-Arg, Arg-Tyr, and Ala-Arg.

### Claim 14 (depends on 9)

The method of claim 9, wherein the oligopeptide salt is an acetate salt.

### Claim 15 (depends on 9)

The method of claim 9, wherein the oligopeptide salt is a lyophilized powder prior to being placed in solution.

### Claim 16 (depends on 9)

The method of claim 9, wherein the solution further comprises (i) a second oligopeptide comprising arginine and consisting of two to 10 amino acid residues, wherein the second oligopeptide is a dipeptide comprising a basic, acidic, hydrophobic, or aromatic residue, (ii) one or more amino acids, or (iii) mixtures of any thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the second oligopeptide is selected from Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, Ala-Arg, Phe-Arg, and Arg-Tyr and the one or more amino acids are selected from arginine, proline, n-acetyl arginine, n-acetyl lysine, n-acetyl histidine, n-acetyl proline or mixtures of any thereof.

### Claim 18 (depends on 9)

The method of claim 9, wherein viscosity of the formulation is reduced by at least about 30% or at least about 50%.

### Claim 19

A pharmaceutical formulation of tezepelumab, which comprises an excipient selected from arginine, proline, proline and arginine, N-acetyl arginine, Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, or Ala-Arg.

### Claim 20

A pharmaceutical formulation of PCSK9 binding polypeptide, wherein the formulation comprises an excipient selected from Arg-Phe, Arg-Ala, Arg-Val, Pro-Arg, Val-Arg, Ala-Arg, Phe-Arg, Arg-Tyr, and Arg-Phe.
